UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2007

Commission File Number 1-6926

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

New Jersey	730 Central Avenue Murray Hill, New Jersey 07974	22-1454160
(State of incorporation)	(Address of principal executive offices)	(I.R.S. Employer Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  x Accelerated filer  ¨ Non-accelerated filer  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class	Outstanding at June 30, 2007
Common Stock - $0.25 par value	103,359,171

C. R. BARD, INC. AND SUBSIDIARIES

INDEX

		PAGE NO.
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Balance Sheets – June 30, 2007 and December 31, 2006	3
	Condensed Consolidated Statements of Income For the Quarter and Six Months Ended June 30, 2007 and 2006	4
	Condensed Consolidated Statements of Shareholders’ Investment For the Six Months Ended June 30, 2007 and 2006	5
	Condensed Consolidated Statements of Cash Flows For the Six Months Ended June 30, 2007 and 2006	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	41
Item 4.	Controls and Procedures	41
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 4.	Submission of Matters to a Vote of Security Holders	44
Item 5.	Other Information	44
Item 6.	Exhibits	45
SIGNATURES		46

2

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except shares and par values, unaudited)

	June 30, 2007			December 31, 2006
ASSETS
Current assets:
Cash and cash equivalents	$	497,500		$	416,200
Short-term investments		122,300			101,000
Accounts receivable, less allowances of $16,100 and $15,700, respectively		343,400			334,100
Inventories		239,600			224,300
Short-term deferred tax assets		33,100			32,800
Other current assets		42,000			24,500
Assets of discontinued operations		100			1,000
Total current assets		1,278,000			1,133,900
Net property, plant and equipment		344,100			342,700
Intangibles		758,800			721,900
Deferred tax assets		44,800			32,500
Other assets		61,000			46,200
Total assets	$	2,486,700		$	2,277,200
LIABILITIES AND SHAREHOLDERS’ INVESTMENT
Current liabilities:
Short-term borrowings and current maturities of long-term debt	$	800		$	—
Accounts payable		53,300			57,800
Accrued compensation and benefits		76,900			93,800
Accrued expenses		99,800			101,100
Income taxes payable		10,500			36,300
Liabilities of discontinued operations		—			300
Total current liabilities		241,300			289,300
Long-term debt		149,800			150,600
Other long-term liabilities		181,500			117,400
Deferred income taxes		23,300			21,900
Commitment and contingent liabilities (Note 11)
Shareholders’ investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued		—			—
Common stock, $0.25 par value, authorized 600,000,000 shares at June 30, 2007 and December 31, 2006; issued and outstanding 103,359,171 shares at June 30, 2007 and 103,155,437 shares at December 31, 2006		25,800			25,800
Capital in excess of par value		749,600			659,700
Retained earnings		1,119,900			1,026,800
Accumulated other comprehensive income (loss)		(4,500	)		(14,300	)
Total shareholders’ investment		1,890,800			1,698,000
Total liabilities and shareholders’ investment	$	2,486,700		$	2,277,200

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

3

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars and shares in thousands except per share amounts, unaudited)

	For the Quarter Ended June 30,						For the Six Months Ended June 30,
	2007			2006			2007			2006
Net sales	$	545,700		$	496,500		$	1,073,900		$	962,400
Costs and expenses:
Cost of goods sold		216,600			194,800			423,100			372,900
Marketing, selling and administrative expense		160,500			153,300			314,200			295,600
Research and development expense		35,100			37,200			65,200			75,500
Interest expense		3,000			4,500			5,900			9,200
Other (income) expense, net		(8,800	)		(7,600	)		(16,200	)		(15,300	)
Total costs and expenses		406,400			382,200			792,200			737,900
Income from continuing operations before tax provision		139,300			114,300			281,700			224,500
Income tax provision		41,800			33,200			82,600			61,900
Income from continuing operations	$	97,500		$	81,100		$	199,100		$	162,600
Discontinued operations: (Note 2)
Income (loss) from operations of Tegress™	$	—		$	300		$	100		$	—
Income tax provision		—			—			100			100
Income (loss) on discontinued operations	$	—		$	300		$	—		$	(100	)
Net income	$	97,500		$	81,400		$	199,100		$	162,500
Basic earnings (loss) per share:
Income from continuing operations	$	0.94		$	0.78		$	1.93		$	1.57
Income (loss) on discontinued operations		—			—			—			—
Net income per share	$	0.94		$	0.79		$	1.93		$	1.57
Diluted earnings (loss) per share:
Income from continuing operations	$	0.91		$	0.76		$	1.86		$	1.52
Income (loss) on discontinued operations		—			—			—			—
Net income per share	$	0.91		$	0.76		$	1.86		$	1.52
Weighted average common shares outstanding - basic		103,600			103,500			103,400			103,700
Weighted average common shares outstanding - diluted		106,900			107,000			106,800			107,000

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

4

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ INVESTMENT

(dollars in thousands except shares, unaudited)

	Common Stock					Capital in Excess of Par Value		Retained Earnings			Accumulated Other Comp. Inc./(Loss)			Total
	Shares		Amount
Balance at December 31, 2006	103,155,437		$	25,800		$	659,700	$	1,026,800		$	(14,300	)	$	1,698,000
Net income									199,100						199,100
Available for sale securities (net of $0 taxes)												(100	)		(100	)
Change in derivative instruments designated as cash flow hedges (net of $0 taxes)												200			200
Amortization of pension items included in net periodic pension cost (net of $1,900 taxes)												1,000			1,000
Foreign currency translation adjustment												8,700			8,700
Total comprehensive income									199,100			9,800			208,900
Issuance of common stock	1,183,734			200			43,200								43,400
Share-based compensation							22,700								22,700
Purchase of common stock for treasury	(980,000	)		(200	)				(81,100	)					(81,300	)
Adjustment for the adoption of FIN 48 (Note 3)									5,300						5,300
Cash dividends declared in current year									(30,200	)					(30,200	)
Tax benefit relating to employee stock plans							24,000								24,000
Balance at June 30, 2007	103,359,171		$	25,800		$	749,600	$	1,119,900		$	(4,500	)	$	1,890,800
Balance at December 31, 2005	104,012,498		$	26,000		$	521,500	$	986,000		$	2,600		$	1,536,100
Net income									162,500						162,500
Available for sale securities (net of $1,600 taxes)												(3,000	)		(3,000	)
Change in derivative instruments designated as cash flow hedges (net of $1,200 taxes)												(2,500	)		(2,500	)
Foreign currency translation adjustment												29,700			29,700
Total comprehensive income									162,500			24,200			186,700
Issuance of common stock	998,666			300			35,700								36,000
Share-based compensation							18,900								18,900
Purchases of common stock for treasury	(1,497,600	)		(400	)				(102,200	)					(102,600	)
Cash dividend declared in current year									(28,100	)					(28,100	)
Tax benefit relating to employee stock plans							12,600								12,600
Balance at June 30, 2006	103,513,564		$	25,900		$	588,700	$	1,018,200		$	26,800		$	1,659,600

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

5

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)

	For the Six Months Ended June 30,
	2007			2006
Cash flows from operating activities from continuing operations:
Net income	$	199,100		$	162,500
Loss on discontinued operations		—			100
Income from continuing operations		199,100			162,600
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:
Depreciation and amortization		38,800			33,900
Gain on investments		(200	)		(1,600	)
Purchased research and development		1,600			16,800
Deferred income taxes		(3,000	)		(9,900	)
Expenses under stock plans		22,700			18,100
Inventory reserves and provision for doubtful accounts		5,200			6,300
Other noncash items		(1,500	)		300
Changes in assets and liabilities, net of acquired businesses:
Accounts receivable		(4,800	)		(31,300	)
Inventories		(17,000	)		(20,600	)
Other operating assets		(12,600	)		4,000
Current liabilities, excluding debt		10,700			(50,300	)
Pension contributions		(5,000	)		(800	)
Other long-term liabilities		3,700			3,900
Net cash provided by operating activities from continuing operations		237,700			131,400
Cash flows from investing activities from continuing operations:
Capital expenditures		(25,200	)		(37,600	)
Purchase of available-for-sale securities, net		(21,600	)		(97,500	)
Proceeds from investments		200			1,600
Payments made for purchases of businesses, net of cash acquired		(42,000	)		(170,100	)
Patents and other intangibles		(16,600	)		(12,200	)
Net cash used in investing activities from continuing operations		(105,200	)		(315,800	)
Cash flows from financing activities from continuing operations:
Repayments of short-term borrowings		—			(70,000	)
Proceeds from exercises of share-based payment arrangements, net		33,100			28,900
Excess tax benefit relating to employee stock plans		20,800			10,500
Purchase of common stock		(81,300	)		(102,600	)
Dividends paid		(29,100	)		(27,200	)
Net cash used in financing activities from continuing operations		(56,500	)		(160,400	)
Net cash flows from discontinued operations:
Net cash provided by operating activities		600			1,400
Net cash used in investing activities		—			—
Net cash used in financing activities		—			—
Effect of exchange rate changes on cash in discontinued operations		—			—
Net cash provided by discontinued operations		600			1,400
Effect of exchange rate changes on cash and cash equivalents		4,700			9,200
Increase (decrease) in cash and cash equivalents during the period		81,300			(334,200	)
Balance at January 1		416,200			754,200
Balance at June 30	$	497,500		$	420,000

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

6

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

Nature of Operations - C. R. Bard, Inc. (the “company” or “Bard”) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company markets its products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. Bard holds strong market positions in vascular, urology, oncology and surgical specialty products. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to consolidated financial statements contained in the company’s Annual Report on Form 10-K/A for the year ended December 31, 2006. These condensed consolidated financial statements have not been audited. These statements have been prepared on a basis that is substantially consistent with the accounting principles applied in our Annual Report on Form 10-K/A for the year ended December 31, 2006. In our opinion, these financial statements include all normal and recurring adjustments necessary for a fair presentation. The results for the quarter and six months ended June 30, 2007 are not necessarily indicative of the results expected for the year.

Consolidation - The consolidated financial statements include the accounts of the company and its majority-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter ended May 31, 2007 and 2006 and as of November 30, 2006. No events occurred related to these foreign subsidiaries during the months of June 2007, June 2006 or December 2006 that materially affected the financial position or results of operations of the company. In addition, the company evaluates its relationships with other entities to identify whether they are variable interest entities as defined by Financial Accounting Standards Board (“FASB”) Interpretation No. 46 (R) Consolidation of Variable Interest Entities (“FIN 46R”) and to assess whether it is the primary beneficiary of such entities. If the determination is made that the company is the primary beneficiary, then that entity is included in the consolidated financial statements in accordance with FIN 46R. The company has no unconsolidated subsidiaries and no special purpose entities.

Use of Estimates - The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. The company evaluates these estimates and judgments on an ongoing basis and bases its estimates on historical experience, current conditions and various other assumptions that are believed to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities as well as identifying and assessing the accounting treatment with respect to commitments and contingencies. Actual results may differ from these estimates under different assumptions or conditions.

Reclassifications - Certain prior-year amounts have been reclassified to conform to the current year presentation.

Revenue Recognition - Bard markets its products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. The company sells directly to these end-users as well as to independent distributors.

The company’s net sales represent gross sales invoiced to both end-users and independent distributors, less certain related charges, including discounts, returns, rebates and other allowances. The company recognizes product revenue when persuasive evidence of a sales arrangement exists, title and risk of loss have transferred, the selling price is fixed or determinable, contractual obligations have been satisfied and collectibility is reasonably assured. Unless agreed otherwise, the company’s terms with domestic distributors provide that title

7

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

and risk of loss pass F.O.B. origin. Certain sales to domestic and European distributors are F.O.B. destination. For arrangements where the company’s terms state F.O.B. destination, the company records sales on this basis.

In certain circumstances, end-users may require the company to maintain consignment inventory at the end-user’s location. In the case of consignment inventories, revenues and associated costs are recognized upon the notification of usage by the customer.

Charges for discounts, returns, rebates and other allowances are recognized as a deduction from revenue on an accrual basis in the period in which the revenue is recorded. The accrual for product returns, discounts and other allowances is based on the company’s history. The company allows customers to return defective or damaged products. Historically, product returns have not been material. The company grants sales rebates to independent distributors based upon the distributor’s reporting of end-user sales and pricing. Sales rebates are accrued by the company in the period in which the sale is recorded. The company’s rebate accrual is based on its history of actual rebates paid. In estimating rebate accruals, the company considers the lag time between the point of sale and the payment of the distributor’s rebate claim, distributor-specific trend analysis and contractual commitments including stated rebate rates. The company’s reserves for rebates are reviewed at each reporting period and adjusted to reflect data available at that time. The company adjusts reserves to reflect any differences between estimated and actual amounts. Such adjustments impact the amount of net product sales revenue recognized by the company in the period of adjustment.

Shipping and Handling Costs - Shipping and handling costs are included in cost of sales.

Research and Development - Research and development expenses are comprised of expenses related to internal research and development activities, milestone payments for third-party research and development activities and purchased research and development (“purchased R&D”) costs arising from the company’s business development activities. The components of internal research and development expense include: salary and benefits, allocated overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract services and other costs. All research and development costs are expensed as incurred.

Share-Based Compensation - The company accounts for share-based compensation in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 123 (revised 2004), Share-Based Payment (“FAS 123R”), as interpreted by Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 107. Under the fair value provisions of this statement, share-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the date of grant, the company utilizes a binomial model. Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free interest rate and dividend yield. The risk-free interest rate and dividend yield are based on factual data derived from public sources. The expected stock-price volatility and option life assumptions require significant judgment which makes them critical accounting estimates.

The company’s expected volatility is based upon weightings of the historical volatility of the company’s stock and the implied volatility from publicly traded options. The company reviews the trading volumes and option life of its publicly traded options in order to determine the appropriate weighting of implied volatility. This approach is used as a predictor of future realized and implied volatilities and is directly related to stock option valuations.

With respect to the weighted-average option life assumption, the company considers the exercise behavior of past grants and models the pattern of aggregate exercises.

8

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As share-based compensation expense recognized in the consolidated statement of income is based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. The company estimates forfeitures at the time of grant based on historical experience and revises estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Earnings Per Share - “Basic earnings per share” represents net income divided by the weighted average shares outstanding. “Diluted earnings per share” represents net income divided by weighted average shares outstanding adjusted for the incremental dilution of outstanding stock options and awards. Unless indicated otherwise, per share amounts are calculated on a diluted basis.

Treasury Stock - In fiscal 1998, the company began holding repurchased shares of its common stock as treasury stock. The company accounts for these treasury stock purchases as retirements reducing retained earnings by the cost of the repurchase. Reissuances of these treasury shares are accounted for as new issuances. There were approximately 12.9 million treasury shares at June 30, 2007 and approximately 13.0 million treasury shares at December 31, 2006.

Income Taxes - All income tax amounts reflect the use of the liability method. Under this method, deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences and the corresponding reported amount in the financial statements. Effective January 1, 2007, the company adopted FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109 (“FIN 48”). See Note 3 Income Tax Expense in these notes to condensed consolidated financial statements.

Income Statement Presentation of Taxes Collected from Customers and Remitted to Government Authorities - The company follows a net basis policy with regard to sales, use, value added or any other tax assessed by a government authority, which excludes them from both net sales and expenses.

Supplemental and Noncash Disclosures of Cash Flow Information - For the six months ended June 30, 2007 and 2006, cash paid for interest was $5.9 million and $8.9 million, respectively. For the six months ended June 30, 2007 and 2006, cash paid for income taxes was $60.6 million and $89.9 million, respectively. For the six months ended June 30, 2007, noncash transactions were $3.0 million for accrued milestone payments, $0.2 million for accrued acquisition costs related to the purchase of a business and $15.6 million for dividends declared and not paid. For the six months ended June 30, 2006, noncash transactions were $0.6 million for accrued acquisition costs related to the purchase of a business and $14.6 million for dividends declared and not paid.

Concentration Risks - The company is potentially subject to financial instrument concentration of credit risk through its cash investments and trade accounts receivable. To mitigate these risks, the company maintains cash and cash equivalents, short-term investments and certain other financial instruments with various major financial institutions. The company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. Concentrations of risk with respect to trade accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. However, a significant amount of trade receivables is with national healthcare systems in several countries. Although the company does not currently foresee a credit risk associated with these receivables, repayment is dependent upon the financial stability of those countries’ national economies. Sales to distributors, which supply the company’s products to many end-users, accounted for approximately 33% of the company’s net sales in 2006, and the five largest distributors combined, including Medicon, Inc., the company’s joint venture in Japan, accounted for approximately 70% of such sales.

Software Capitalization - Internally used software, whether purchased or developed, is capitalized and amortized using the straight-line method over an estimated useful life of five to seven years. Capitalized software costs are included in machinery and equipment. In accordance with Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use, the company capitalizes certain costs associated with

9

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

internal-use software such as the payroll costs of employees devoting time to the projects and external direct costs for materials and services. Costs associated with internal-use software are expensed during the design phase until the point at which the project has reached the development stage. Subsequent additions, modifications or upgrades to internal- use software are capitalized only to the extent that they allow the software to perform a task it previously did not perform. Software maintenance and training costs are expensed in the period in which they are incurred. The capitalization of software requires judgment in determining when a project has reached the development stage and the period over which the company expects to benefit from the use of that software.

Impairment of Long-Lived Assets - The company reviews long-lived assets, such as property, plant and equipment, and purchased intangibles subject to amortization for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The company evaluates the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair market value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair market value less costs to sell, and would no longer be depreciated.

Goodwill and Acquired Intangible Assets - Goodwill and intangible assets that have indefinite useful lives are not amortized but rather are tested for impairment annually or more frequently if impairment indicators arise. None of the company’s intangible assets have an indefinite life. Intangible assets with determinable lives are amortized on a straight-line basis over their useful lives. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated costs were based on respective fair market values of identifiable assets at the date of acquisition.

New Accounting Pronouncements - In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“FAS 157”), which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The provisions of FAS 157 are effective as of the beginning of Bard’s 2008 fiscal year. The company does not expect the adoption of FAS 157 to have a material impact on its financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—including an amendment of FASB Statement No. 115 (“FAS 159”). FAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. FAS 159 is expected to expand the use of fair value measurement, which is consistent with the long-term measurement objectives for accounting for financial instruments. FAS 159 is effective as of the beginning of Bard’s 2008 fiscal year with early adoption permitted. The company does not expect the adoption of FAS 159 to have a material impact on its financial statements.

2. Acquisitions and Divestitures

Tegress^TM Withdrawal - The company withdrew from the synthetic bulking market and discontinued sales of its Tegress^TM product effective January 31, 2007 and in accordance with SFAS No.144, Accounting for the Impairment or Disposal of Long-Lived Assets (“FAS 144”) has accounted for this withdrawal as a discontinued operation. The withdrawal was based upon a strategic review of the Tegress^TM synthetic bulking product, which considered the product’s limited commercial success to date, significant future clinical costs and uncertain growth potential. During the fourth quarter of 2006, the company recorded an impairment charge and related costs associated with Tegress^TM of approximately $46.4 million pretax.

10

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Condensed financial information related to the discontinued operation is as follows:

	For the Quarter Ended June 30,				For the Six Months Ended June 30,
	2007		2006		2007	2006
(dollars in millions)
Net sales	$	—	$	1.7	0.3	3.3
Pretax income from operations		—		0.3	0.1	—
Income tax provision		—		—	0.1	0.1
Income (loss) on discontinued operations		—		0.3	—	(0.1	)

For the six months ended June 30, 2007 Tegress^TM cash flows of $0.6 million relate to the collection of customer receivables arising prior to January 31, 2007 and the wind-down of clinical studies, leases and intellectual property matters. There are no significant environmental or product liabilities associated with the discontinued operations.

Inrad, Inc. - On June 13, 2007, the company acquired the assets of Inrad Inc.’s biopsy marker business for $33.0 million. This product line is included in our vascular disease state category. The total purchase price of $33.9 million includes capitalized acquisition costs for legal and other consulting costs. The company has a contingent payment of $0.3 million that will be due upon the delivery of certain equipment. The company considered a variety of factors, including appraisals, comparable transactions, relief from royalty analysis and other discounted cash-flow approaches in determining purchase price allocations. The purchase price allocation that follows is preliminary as of June 30, 2007 and is expected to be finalized by year-end 2007.

(dollars in millions)
Current assets	$	0.6
Core technology	$	30.8	(Estimated useful life of 13 yrs)
Other intangibles	$	0.3	(Estimated useful life of 5 yrs)
Purchased R&D	$	1.6
Goodwill	$	0.6
Total	$	33.9

The purchased R&D of $1.6 million relates to a biopsy marker device in development at the time of the acquisition. The company recorded the purchased R&D charge in research and development expense in its consolidated statements of income. The value assigned to purchased R&D was determined by identifying a specific purchased R&D project that would be continued and for which (a) technological feasibility had not been established at acquisition date, (b) there was no alternative future use and (c) the fair market value was estimable with reasonable reliability.

3. Income Tax Expense

In July 2006, the FASB issued FIN 48. FIN 48 prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return. FIN 48 states that a tax benefit from an uncertain tax position may be recognized only if it is “more likely than not” that the position is sustainable, based on its technical merits. The tax benefit of a qualifying position is the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority having full knowledge of all relevant

11

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

information. A tax benefit from an uncertain position was previously recognized if it was probable of being sustained. Under FIN 48, the liability for unrecognized tax benefits is classified as noncurrent unless the liability is expected to be settled in cash within 12 months of the reporting date. FIN 48 is effective as of the beginning of the first fiscal year beginning after December 15, 2006. The company adopted the provisions of FIN 48 on January 1, 2007. The impact of adopting FIN 48 on the company’s consolidated financial statements is summarized below.

	Balance at December 31, 2006		FIN 48 Adjustment		Balance at January 1, 2007
(dollars in millions)
Accrued expenses	$	107.7	(9.5	)	$	98.2
Income taxes payable	$	36.3	(44.1	)	$	(7.8	)
Other long-term liabilities	$	110.8	48.3		$	159.1
Retained earnings	$	1,026.8	5.3		$	1,032.1

The company operates in multiple taxing jurisdictions, both within the United States and outside of the United States, and faces audits from various tax authorities regarding transfer pricing, the deductibility of certain expenses, intercompany transactions as well as other matters. At January 1, 2007, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was approximately $45.0 million (of which $42.0 million would impact the effective tax rate if recognized) plus approximately $8.0 million of accrued interest. As of June 30, 2007, the corresponding balance of liability for unrecognized tax benefits is approximately $50.0 million (of which $46.0 million would impact the effective tax rate if recognized) for the items described above plus approximately $10.0 million of accrued interest.

The company is currently under examination in several tax jurisdictions and remains subject to examination until the statute of limitations expires for the respective tax jurisdiction. Within specific countries, the company may be subject to audit by various tax authorities, or subsidiaries operating within the country may be subject to different statute of limitations expiration dates. As of June 30, 2007, a summary of the tax years that remain subject to examination in the company’s major tax jurisdictions are:

United States - federal	2003 and forward
United States – states	2002 and forward
Germany	2002 and forward
Malaysia	2000 and forward
Puerto Rico	2002 and forward
United Kingdom	2004 and forward

Based upon the expiration of statutes of limitations and/or the conclusion of tax examinations in several jurisdictions, the company believes it is reasonably possible that the total amount of previously unrecognized tax benefits for the items discussed above may decrease by up to $20.0 million within 12 months of June 30, 2007.

The company’s policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense. The company does not consider this interest part of its fixed charges.

4. Financial Instruments

Cash equivalents are highly liquid investments purchased with an original maturity of ninety days or less and amounted to $467.1 million and $394.1 million at June 30, 2007 and December 31, 2006, respectively.

12

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The company accounts for short-term investments in accordance with SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities. The company determines the appropriate classification of all short-term investments as held-to-maturity, available-for-sale or trading at the time of purchase and re-evaluates such classifications as of each balance sheet date. There were no investments classified as trading at June 30, 2007 and December 31, 2006. All of the outstanding short-term investments at June 30, 2007 and December 31, 2006 mature within one year. Unrealized gains and losses, net of taxes, are reported as a component of accumulated other comprehensive income (loss) in shareholders’ investment. There were no realized gains or losses on short-term investments reported in the six months ended June 30, 2007 and the year ended December 31, 2006. The amortized cost, gross unrealized gains (losses) and fair value for short-term investments by major security type at June 30, 2007 and December 31, 2006 were as follows:

	June 30, 2007
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)			Fair Value
(dollars in millions)
Held-to-maturity:
Time deposits	$	1.0	$	—	$	—		$	1.0
Available-for-sale:
Corporate debt securities		120.9		0.5		(0.1	)		121.3
Total short-term investments	$	121.9	$	0.5	$	(0.1	)	$	122.3
	December 31, 2006
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)			Fair Value
(dollars in millions)
Held-to-maturity:
Time deposits	$	2.6	$	—	$	—		$	2.6
Available-for-sale:
Corporate debt securities		98.1		0.3		—			98.4
Total short-term investments	$	100.7	$	0.3	$	—		$	101.0

Because the company has the ability and intent to hold these investments until a recovery of fair value, which may be at maturity, the company does not consider any unrealized loses to be other than temporary at June 30, 2007.

Investments in equity securities that have readily determinable fair market values are classified and accounted for as available-for-sale securities in other current assets. Available-for-sale equity securities are recorded at fair market value, with the change in fair market value recorded, net of taxes, as a component of accumulated other comprehensive income (loss). The fair market value of available-for-sale equity securities was approximately $4.7 million and $4.5 million at June 30, 2007 and December 31, 2006, respectively. In the quarter ended June 30, 2007, the company donated equity securities with a fair market value of approximately $0.4 million to the company’s charitable foundation. For the six months ended June 30, 2007, the company donated equity securities with a fair market value of approximately $0.8 million to the company’s charitable foundation.

13

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

5. Inventories

Inventories are stated at the lower of cost or market. Cost components include material, labor and manufacturing overhead. For most domestic divisions, cost is determined using the last-in-first-out (“LIFO”) method. Approximately 62% of the company’s inventory costs are determined using LIFO. For all other inventories, cost is determined using the first-in-first-out (“FIFO”) method. Due to changing technologies and cost containment, the difference between the valuation under the LIFO method and the FIFO method is not significant. The following is a summary of inventories:

	June 30, 2007		December 31, 2006
(dollars in millions)
Finished goods	$	145.6	$	139.5
Work in process		23.1		20.0
Raw materials		70.9		64.8
Total	$	239.6	$	224.3

6. Property, Plant and Equipment

Property, plant and equipment are stated at cost. Major renewals and improvements are capitalized, while maintenance and repairs are expensed when incurred. Depreciation is computed over the estimated useful lives of depreciable assets using the straight-line method. The following is a summary of property, plant and equipment:

	June 30, 2007		December 31, 2006
(dollars in millions)
Property, plant and equipment, at cost:
Land	$	14.6	$	14.5
Buildings and improvements		220.1		214.8
Machinery and equipment		362.1		341.0
		596.8		570.3
Less - accumulated depreciation and amortization		252.7		227.6
Net property, plant and equipment	$	344.1	$	342.7

Useful lives for property and equipment are as follows:

Buildings and improvements	1 to 40 years
Machinery and equipment	1 to 20 years

Depreciation expense was approximately $12.5 million and $11.5 million for the quarters ended June 30, 2007 and 2006, respectively. Depreciation expense was approximately $24.3 million and $22.2 million for the six months ended June 30, 2007 and 2006, respectively. The company capitalized $2.5 million and $2.3 million of internal-use software for the six months ended June 30, 2007 and 2006, respectively.

7. Intangible Assets

Goodwill and intangible assets that have indefinite useful lives are not amortized but rather are tested for impairment annually or more frequently if impairment indicators arise. None of the company’s intangible assets have an indefinite life. Intangible assets with determinable lives are amortized on a straight-line basis over their useful lives. Goodwill and intangible assets have been recorded at either incurred or allocated cost. Allocated

14

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

costs were based on respective fair market values of identifiable assets at the date of acquisition. The company has generally assigned goodwill recorded in connection with an acquisition to its four reporting units, each of which is one level below the company’s single reporting segment, based on the reporting unit which sponsored the acquisition. An impairment loss is recognized to the extent that the carrying amount exceeds the reporting unit’s fair market value.

The balances of goodwill and intangible assets are as follows:

	June 30, 2007
	Gross Carrying Value		Accumulated Amortization			Translation		Net Carrying Value		Wt. Avg. Useful Life (years)
(dollars in millions)
Patents	$	247.7	$	(50.4	)	$	—	$	197.3	15
Distribution agreements		21.9		(11.4	)		—		10.5	14
Licenses		16.3		(6.8	)		—		9.5	9
Core technologies		65.3		(8.3	)		—		57.0	11
Customer relationships		42.6		(11.3	)		—		31.3	9
Other intangibles		14.1		(3.0	)		—		11.1	10
Goodwill		533.1		(93.3	)		2.3		442.1	—
Total	$	941.0	$	(184.5	)	$	2.3	$	758.8
	December 31, 2006
	Gross Carrying Value		Accumulated Amortization			Translation		Net Carrying Value		Wt. Avg. Useful Life (in years)
(dollars in millions)
Patents	$	241.1	$	(42.1	)	$	—	$	199.0	15
Distribution agreements		21.9		(10.6	)		—		11.3	20
Licenses		15.9		(5.9	)		—		10.0	10
Core technologies		23.1		(7.0	)		0.6		16.7	16
Customer relationships		42.6		(9.0	)		—		33.6	10
Other intangibles		12.9		(2.2	)		—		10.7	13
Goodwill		532.5		(93.3	)		1.4		440.6	—
Total	$	890.0	$	(170.1	)	$	2.0	$	721.9

Amortization expense was approximately $7.5 million and $6.8 million for the quarters ended June 30, 2007 and 2006, respectively. Amortization expense was approximately $14.5 million and $11.7 million for the six months ended June 30, 2007 and 2006, respectively.

15

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

8. Short-Term Borrowings and Long-Term Debt

The components of short-term borrowings and long-term debt consisted of:

	June 30, 2007		December 31, 2006
(dollars in millions)
Short-Term Borrowings
Current portion of long-term debt	$	0.8	$	—
Total	$	0.8	$	—
Long-Term Debt
6.70% notes due 2026	$	149.8	$	149.8
Other		—		0.8
Total	$	149.8	$	150.6
Total Debt	$	150.6	$	150.6

On June 28, 2007, the company amended its existing domestic syndicated bank credit facility with a $400 million five-year credit agreement that expires in June 2012. The amended credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. There were no outstanding borrowings or commercial paper borrowings at June 30, 2007 and December 31, 2006. In addition, on October 21, 2005, a wholly owned foreign subsidiary of the company entered into a $250 million syndicated bank credit facility to be used for general corporate needs, including in support of the company’s decision in 2005 to repatriate undistributed foreign earnings under the American Jobs Creation Act of 2004 (the “AJCA”). Loans under the facility bear interest at the company’s option at a fixed spread to LIBOR or the higher of prime rate and 0.50% over the federal funds rate. The facility expires in October 2008. There were no outstanding borrowings under the facility at June 30, 2007 and December 31, 2006.

At June 30, 2007 and December 31, 2006, the company had $149.8 million of unsecured notes that mature in 2026 and pay a semi-annual coupon of 6.70%. The coupon interest closely approximates the effective annual cost of the notes. The market value of the notes approximated $153.4 million at June 30, 2007.

Certain of the company’s debt agreements contain customary representations, warranties and default provisions as well as restrictions that, among other things, require the maintenance of operating cash flow levels and limit the amount of debt that the company may have outstanding. As of June 30, 2007, the company was in compliance with all such financial covenants.

9. Other Long-Term Liabilities

The following is a summary of the components of long-term liabilities:

	June 30, 2007		December 31, 2006
(dollars in millions)
Pension, postretirement benefits and long-term compensation	$	94.1	$	93.0
Income taxes		50.8		—
Product liability accruals and other long-term liabilities		29.0		17.8
Minority interest		7.6		6.6
Total long-term liabilities	$	181.5	$	117.4

16

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

10. Derivative Instruments

Bard’s objective in managing its exposures to foreign currency fluctuations is to minimize earnings and cash flow volatility associated with assets, liabilities and anticipated commitments denominated in foreign currencies. The company does not utilize derivative instruments for trading or speculation purposes. No derivative instruments extend beyond December 2007. The company has formally documented the relationships between hedging instruments and hedged items, as well as its risk management objectives. All derivative instruments are recognized on the balance sheet at fair market value. Hedge accounting is followed for derivatives that have been designated and qualify as fair market value and cash flow hedges. For derivatives that have been designated and qualify as fair market value hedges, the changes in the fair market value of highly effective derivatives, along with changes in the fair market value of the hedged assets that are attributable to the hedged risks, are recorded in current period earnings. For derivatives that have been designated and qualify as cash flow hedges, changes in the fair market value of the effective portion of the derivatives’ gains or losses are reported in other comprehensive income. At June 30, 2007 and December 31, 2006, all derivative instruments utilized were highly effective hedging instruments because they were denominated in the same currency as the hedged item and because the maturities of the derivative instruments matched the timing of the hedged items. It is the company’s policy that when a derivative instrument settles, the associated amounts in accumulated other comprehensive income are reversed to cost of goods sold or other (income) expense, net as appropriate. It is the company’s policy that in the event that (1) an anticipated hedged transaction is determined to be not likely to occur or (2) it is determined that a derivative instrument is no longer effective in offsetting changes in the hedged item, the company would reverse the associated amounts in accumulated other comprehensive income to other (income) expense, net.

The company enters into readily marketable traded forward contracts and options with financial institutions to help reduce the exposure to fluctuations between certain currencies. These contracts limit volatility because gains and losses associated with exchange rate movements are generally offset by movements in the underlying hedged item.

The table below shows the notional amounts and fair market value of the company’s currency-related forward contracts and purchased options as of June 30, 2007 and December 31, 2006, respectively.

	June 30, 2007				December 31, 2006
	Notional Value		Fair Value		Notional Value		Fair Value
(dollars in millions)
Forward currency agreements	$	16.2	$	0.8	$	30.7	$	1.1
Option contracts	$	32.0	$	—	$	64.0	$	0.5

A roll forward of the notional value of the company’s currency-related forward contracts and options for the six months ended June 30, 2007 is as follows:

	Forward currency agreements			Option contracts
(dollars in millions)
December 31, 2006 notional value	$	30.7		$	64.0
New agreements		2.2			—
Expired/cancelled agreements		(16.7	)		(32.0	)
June 30, 2007 notional value	$	16.2		$	32.0

17

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The fair market value of derivative instruments was estimated by discounting expected cash flows using quoted foreign exchange rates as of June 30, 2007 and December 31, 2006. Judgment was employed in developing estimates of fair market value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have an effect on the estimated fair market value amounts. At June 30, 2007, the net fair market value of option contracts and the incremental mark-to-market of forward currency agreements are recorded in either other current assets or accrued expenses in the consolidated balance sheet. For the six months ended June 30, 2007, the company reclassified a loss of approximately $0.5 million from accumulated other comprehensive income to other (income) expense, net and cost of goods sold in the consolidated statement of income as hedged intercompany balances were settled and as anticipated currency needs arose. This reclassification was net of $0.2 million of associated tax effects.

11. Commitments and Contingencies

Product Warranty - The majority of the company’s products are intended for single use; therefore, the company requires limited product warranty accruals. Certain of the company’s products carry limited warranties that in general do not exceed one year from sale. The company accrues estimated product warranty costs at the time of sale and any additional amounts are recorded when such costs are probable and can be reasonably estimated. The following is a summary of activity in the product warranty accrual:

	Beginning Balance December 31, 2006		Charges to Costs and Expenses		Deductions			Ending Balance June 30, 2007
(dollars in millions)
Product warranty accruals	$	2.1	$	1.1	$	(1.0	)	$	2.2

Environmental Remediation - The company accrues for losses associated with environmental remediation obligations when such losses are probable and reasonably estimable. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study. Such accruals are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable.

Legal - In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company were to be determined to be invalid or unenforceable, the company might be required to reduce the value of the patent on the company’s balance sheet and to record a corresponding charge, which could be significant in amount.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known

18

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for any remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined.

The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial position or liquidity. However, one or more of the proceedings could be material to the company’s business and results of operations for a future period.

On November 27, 2006, the company’s Urological Division received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes. The subpoena seeks documents related to the Division’s brachytherapy business. The company is cooperating with the government’s request and is in the process of responding to the subpoena. The inquiry is in a preliminary stage and, therefore, the likelihood of an adverse outcome cannot be assessed at this time. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period.

Approximately 100 federal and state lawsuits involving individual claims, as well as three putative class actions, have been filed or asserted against the company with respect to its Bard^® Composix^® Kugel^® product intended for ventral hernia repair (collectively, the “Composix Claims”). The company voluntarily recalled certain sizes and lots of the product beginning in December 2005. The actions generally seek damages for personal injury resulting from use of the product and the putative class actions, none of which has been certified, also seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. On June 22, 2007, the Judicial Panel on Multidistrict Litigation transferred Composix lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings. The federal actions have been transferred to the United States District Court for the District of Rhode Island.

The Composix Claims are at an early stage and, therefore, the company cannot reasonably predict the outcome of the proceedings or determine an estimate, or a range of estimates, of potential damages, nor the time frame in which they may be resolved. While the company intends to vigorously defend the Composix Claims, it cannot give any assurances that the Composix Claims will not have a material adverse impact on the company’s result of operations in a future period or the company’s financial position or liquidity.

On February 21, 2007, Southeast Missouri Hospital filed a putative class action complaint on behalf of itself and all others similarly situated against the company and another manufacturer under the caption Southeast Missouri Hospital v. C. R. Bard, Inc., et al. (Civil Action No. 1:07-cv-00031, United States District Court, Eastern District of Missouri, Southeastern District). The plaintiff alleges that the company and the other defendant conspired to exclude competitors from the market and to maintain the company’s market share by engaging in conduct in violation of state and federal antitrust laws. The plaintiff seeks injunctive relief and money damages. Antitrust damages are subject to trebling. The company intends to defend this matter vigorously. At this time, it is not possible to assess the likelihood of an adverse outcome or determine an

19

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

estimate, or a range of estimates, of potential damages. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period or the company’s financial position or liquidity.

12. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2003 Long Term Incentive Plan of C. R. Bard, Inc. (the “2003 Plan”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc. (the “Directors’ Plan”) to certain directors, officers and employees. The total number of remaining shares at June 30, 2007 that may be issued under the 2003 Plan was 3,762,111 and under the Directors’ Plan was 121,966. Awards under the 2003 Plan may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company has two employee share purchase programs.

Amounts recognized in the financial statements for share-based compensation are as follows:

	For the Quarter Ended June 30,				For the Six Months Ended June 30,
	2007		2006		2007		2006
(dollars in millions)
Total cost of share-based payment plans	$	11.0	$	8.9	$	23.1	$	18.8
Amounts capitalized in inventory and fixed assets		0.4		0.3		0.4		0.7
Amounts charged against income before income tax benefit	$	10.6	$	8.6	$	22.7	$	18.1
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets	$	0.3	$	0.2	$	0.8	$	0.2
Amount of related income tax benefit recognized in income	$	3.4	$	3.0	$	7.6	$	6.3

As of June 30, 2007, there was approximately $51.2 million of unrecognized compensation costs related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately three years. The company repurchases shares, from time to time, on the open market to satisfy share-based payment arrangements. The company has sufficient treasury shares to satisfy expected share-based payment arrangements for the remainder of the year.

Nonvested Restricted Stock Unit Awards—The company granted restricted stock units to certain employees. These restricted stock units have requisite service periods of seven years. No voting or dividend rights are associated with these grants until the underlying shares are issued upon vesting. No significant activity occurred during the second quarter of 2007. The following table details the activity in the nonvested restricted stock unit awards for the six months ended June 30, 2007:

	For the Six Months Ended June 30, 2007
	Number of Units		Wt. Avg. Grant Date Fair Value
Outstanding - Beginning of period	463,308		$	50.71
Granted	146,705		$	76.66
Vested	—			—
Forfeited	(47,526	)	$	55.94
Outstanding - End of period	562,487		$	57.03

20

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Stock Purchase Program and Plans

Management Stock Purchase Program—The company maintains a management stock purchase program under the 2003 Plan (together with a predecessor stock purchase plan, the “MSPP”). Under the MSPP, employees at a specified level may purchase, with their eligible annual bonus, common stock units at a 30% discount from the lower of the price of the common stock on July 1 of the previous year or on the date of purchase, which occurs on the date bonuses are paid. Employees make an election on or before June 30 of the previous year as to the percentage of their eligible annual bonus that will be used to purchase common stock units under the MSPP. Eligible employees are required to utilize at least 25% of their eligible annual bonuses to purchase common stock units under the MSPP to the extent they have not satisfied certain stock ownership guidelines. MSPP shares or units are restricted from sale or transfer for four years from the purchase date. Only shares or units with a value equal to the 30% discount are forfeited if the employee’s employment terminates prior to the end of the four-year period. For these shares or units, the difference between the market price and the purchase price at the purchase date is amortized ratably over a four-year requisite service period. The expense recognition period for certain individuals will be reduced to match their retirement-eligibility date. Dividends or dividend-equivalents are paid on MSPP shares or units, and the participant has the right to vote all MSPP shares. No significant activity occurred during the second quarter of 2007. The following table details the activity in the MSPP for the six months ended June 30, 2007:

	For the Six Months Ended June 30, 2007
	Number of Shares		Wt. Avg. Fair Value
Outstanding - Beginning of period	311,252		$	50.16
Purchased	57,679		$	80.97
Vested	(63,545	)	$	28.92
Forfeited	(10,130	)	$	63.60
Outstanding - End of period	295,256		$	60.29

Employee Stock Purchase Plan—Under the 1998 Employee Stock Purchase Plan of C. R. Bard, Inc. (“ESPP”), domestic employees and certain foreign employees can purchase Bard stock at a 15% discount to the lesser of the market price on the beginning or ending date of the six-month periods ending June 30 and December 31 of each year. Employees may elect to make after-tax payroll deductions of 1% to 10% of compensation as defined by the plan up to a maximum of $25,000 per year. The ESPP is intended to meet the requirements of Section 423 of the Internal Revenue Code of 1986, as amended. Employee payroll deductions are for six-month periods beginning each January 1 and July 1. Shares of the company’s common stock are purchased on June 30 or December 31 or the following business day, unless either the purchase of such shares was delayed at the election of the participant or the participant’s employment was terminated. Purchased shares are restricted for sale or transfer for a six-month period. All participant funds received prior to the ESPP purchase dates are held as company liabilities without interest or other increment. No dividends are paid on employee contributions until shares are purchased. On January 3, 2007, employees purchased 58,272 shares under the ESPP. On July 2, 2007, employees purchased 59,741 shares under the ESPP.

21

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The company valued the ESPP option utilizing the Black-Sholes method. The following table outlines the assumptions used:

	January 3, 2007 Purchase			July 2, 2007 Purchase
Dividend yield (annual rate)		0.08	%		0.08	%
Risk-free interest rate		5.17	%		5.07	%
Expected option life in years		0.5			0.5
Expected volatility		21	%		21	%
Option value	$	15.67		$	17.85

13. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans that together cover substantially all domestic and certain foreign employees. These plans provide benefits based upon a participant’s compensation and years of service. The nonqualified plans are made up of the following arrangements: a nonqualified supplemental deferred compensation arrangement and a nonqualified excess pension deferred compensation arrangement (“nonqualified plans”). The nonqualified supplemental deferred compensation arrangement provides supplemental income to key executives of the company. The benefit is determined by the accumulation of an account balance that results from a percentage of pay credit and interest. No deferrals of pay are required from participants. The balance is paid to a participant after retirement over a 15-year period. The nonqualified excess pension deferred compensation arrangement provides benefits to key employees that cannot be provided by the qualified plan due to Internal Revenue Service (“IRS”) limitations. The company uses a September 30 measurement date for all of its defined benefit pension plans. The components of net periodic benefit expense for the quarters and six months ended June 30, 2007 and 2006, respectively, are as follows:

	For the Quarter Ended June 30,
	2007								2006
(dollars in millions)	Tax Qualified Plans			Nonqualified Plans		Total			Tax Qualified Plans			Nonqualified Plans		Total
Service cost net of employee contributions	$	3.8		$	0.6	$	4.4		$	3.4		$	0.5	$	3.9
Interest cost		3.2			0.5		3.7			3.0			0.5		3.5
Expected return on plan assets		(4.3	)		—		(4.3	)		(3.9	)		—		(3.9	)
Amortization/settlement/curtailment		1.3			0.1		1.4			1.4			0.1		1.5
Net periodic pension expense	$	4.0		$	1.2	$	5.2		$	3.9		$	1.1	$	5.0
	For the Six Months Ended June 30,
	2007								2006
(dollars in millions)	Tax Qualified Plans			Nonqualified Plans		Total			Tax Qualified Plans			Nonqualified Plans		Total
Service cost net of employee contributions	$	7.6		$	1.2	$	8.8		$	6.8		$	1.0	$	7.8
Interest cost		6.4			1.0		7.4			6.0			1.0		7.0
Expected return on plan assets		(8.6	)		—		(8.6	)		(7.8	)		—		(7.8	)
Amortization/settlement/curtailment		2.6			0.2		2.8			2.8			0.2		3.0
Net periodic pension expense	$	8.0		$	2.4	$	10.4		$	7.8		$	2.2	$	10.0

22

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Other Postretirement Benefit Plans - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except to a limited number of former employees. The measurement date used to determine other postretirement benefit measures for the postretirement benefit plan is December 31. As this plan is unfunded, contributions are made as benefits are incurred. The components of net periodic benefit expense for the quarters and six months ended June 30, 2007 and 2006, respectively, are as follows:

	For the Quarter Ended June 30,				For the Six Months Ended June 30,
(dollars in millions)	2007		2006		2007		2006
Service cost	$	—	$	—	$	—	$	—
Interest cost		0.1		0.2		0.3		0.4
Amortization of unrecognized net loss		0.1		0.1		0.2		0.2
Net periodic benefit expense	$	0.2	$	0.3	$	0.5		0.6

Employer Contributions to Defined Benefit and Other Postretirement Plans - The company’s objective in funding its domestic tax-qualified plan is to accumulate funds sufficient to provide for all benefits and to satisfy the minimum contribution requirements of the Employee Retirement Income Security Act of 1974 (ERISA). Outside the United States, the company’s objective is to fund the international retirement costs over time within the limits of minimum requirements and allowable tax deductions. The company’s annual funding decisions also consider the relationship between each tax-qualified plan’s asset returns compared to the plan’s corresponding expense and consider the relationship between each tax-qualified plan’s benefit obligation and its corresponding funded status. For the six months ended June 30, 2007 and 2006, the company made no required or voluntary contributions to its U.S. tax-qualified plan. For the six months ended June 30, 2007 and 2006, the company made voluntary contributions of $5.0 million and $0.8 million to the company’s non-U.S. tax-qualified plans, respectively. The nonqualified plans include supplemental plans which are generally not funded.

23

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

14. Segment Information from Continuing Operations

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices that are purchased by hospitals, physicians and nursing homes, many of which are used once and discarded. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis. The company’s chief operating decision makers generally evaluate profitability and associated investment on an enterprise-wide basis due to shared infrastructures. The following table represents net sales from continuing operations by geographic region based on the location of the external customer:

	Quarter Ended June 30,				Six Months Ended June 30,
	2007		2006		2007		2006
(dollars in millions)
Net sales:
United States	$	374.8	$	345.8	$	748.7	$	674.4
Europe		105.1		91.9		199.7		173.9
Japan		28.1		24.8		54.5		49.8
Rest of world		37.7		34.0		71.0		64.3
Total net sales	$	545.7	$	496.5	$	1,073.9	$	962.4
Income from continuing operations before tax provision	$	139.3	$	114.3	$	281.7	$	224.5
Long-lived assets	$	1,163.9	$	1,110.8	$	1,163.9	$	1,110.8
Capital expenditures	$	11.4	$	17.3	$	25.2	$	37.6
Depreciation and amortization	$	20.0	$	18.3	$	38.8	$	33.9

The following table represents net sales from continuing operations by disease state management:

	Quarter Ended June 30,				Six Months Ended June 30,
	2007		2006		2007		2006
(dollars in millions)
Net sales:
Vascular	$	135.9	$	119.7	$	263.6	$	233.4
Urology		160.9		147.5		316.1		280.2
Oncology		141.9		117.0		269.7		228.0
Surgical Specialties		86.5		94.5		183.6		182.6
Other products		20.5		17.8		40.9		38.2
Total net sales	$	545.7	$	496.5	$	1,073.9	$	962.4

24

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Overview

The company is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities in the United States and abroad, principally in Europe and Japan. In general, the company’s products are intended to be used once and then discarded or implanted either temporarily or permanently.

The company reports its sales around the concept of disease state management in four major product group categories: vascular, urology, oncology and surgical specialties. The company also has a product group of other products. The company strives to have a leadership position in all of its markets. Approximately 80% of the company’s net sales in 2006 were derived from products in which the company had a number one or number two market leadership position.

The company’s key growth initiatives include continued focus on research and development, the expansion of its sales organization, business development activities, improved manufacturing efficiencies and operating margins. The company’s margins and net income are driven by the company’s ability to generate sales of its products and improve operating efficiency.

The company’s ability to improve sales over time depends in part upon its success in developing and marketing new products. In this regard, the company has strategically increased funding of research and development activities in recent years, with a focus on products and markets that are growing faster than 8% annually. In 2006, the company spent approximately $145.7 million on research and development, an increase of approximately 173% from research and development spending of approximately $53.4 million in 2001. For the quarter ended June 30, 2007, the company spent approximately $35.1 million on research and development compared to $37.2 million in the quarter ended June 30, 2006. Second quarter 2007 spending included payments of $1.6 million for purchased research and development (“purchased R&D”). Second quarter 2006 spending included payments of $6.4 million for purchased R&D. In light of the complexity of the process of developing and bringing new products to market, the company expects a lag of as much as several years before the results of increased research and development spending are reflected in net sales. In addition, there can be no assurance that research and development activities will successfully generate new products or that new products will be successful in the market.

As part of its growth initiatives, the company has increased its sales force by approximately 200 sales positions since 2003. The company believes that its sales force expansions enhance geographic coverage, increase focus on high-growth businesses, facilitate new product introductions and aid in the identification of new product opportunities at the call-point level.

The company also plans to generate increased sales through selective acquisitions of businesses, products and technologies. In general, the company focuses on small to medium acquisitions of products and technologies that complement or expand on the company’s existing product portfolio. In addition, the company may from time to time selectively consider acquisitions of larger, established companies under appropriate circumstances. From time to time, the company may divest lines of business in which the company is not able to reasonably attain or maintain a leadership position or for other strategic reasons. For a discussion of significant acquisitions and dispositions that the company completed during 2006 and the first six months of 2007 see the information in Note 2 Acquisitions and Divestitures in the notes to consolidated financial statements contained in the company’s Annual Report on Form 10-K/A and Note 2 Acquisitions and Divestitures in the notes to the unaudited condensed consolidated financial statements contained in this report.

The company has a comprehensive program aimed at improving manufacturing efficiencies. This program has built on the company’s past restructuring activities and has focused on the improvement of both margins and cash flow.

25

Results of Continuing Operations

Net Sales

The company’s revenues are generated from sales of the company’s products, net of discounts, returns, rebates and other allowances. Bard reported consolidated net sales for the second quarter ended June 30, 2007 of $545.7 million, an increase of 10% on a reported basis over the second quarter ended June 30, 2006 consolidated net sales of $496.5 million. For the second quarter ended June 30, 2007, net sales increased 8% on a constant currency basis over the prior-year period. “Net sales on a constant currency basis” is a non-GAAP financial measure and should not be viewed as a replacement of GAAP results (see “Management’s Use of Non-GAAP Measures” below). Bard reported consolidated net sales for the six months ended June 30, 2007 of $1,073.9 million, an increase of 12% on a reported basis over the six months ended June 30, 2006 consolidated net sales of $962.4 million. For the six months ended June 30, 2007, net sales increased 10% on a constant currency basis over the prior-year period.

The geographic breakdown of net sales by the location of the third-party customer for the quarters and six months ended June 30, 2007 and 2006, respectively, is set forth below.

	Quarter Ended June 30,				Six Months Ended June 30,
	2007		2006		2007		2006
United States	69	%	70	%	70	%	70	%
Europe	19	%	18	%	19	%	18	%
Japan	5	%	5	%	5	%	5	%
Rest of world	7	%	7	%	6	%	7	%
Total net sales	100	%	100	%	100	%	100	%

Price changes had the effect of increasing consolidated net sales for the quarter ended June 30, 2007 by 0.3% compared to the same period in the prior year. Exchange rate fluctuations had the effect of increasing consolidated net sales for the quarter ended June 30, 2007 by 2% as compared to the same period in the prior year. Price changes had the effect of increasing consolidated net sales for the six months ended June 30, 2007 by 0.3% compared to the same period in the prior year. Exchange rate fluctuations had the effect of increasing consolidated net sales for the six months ended June 30, 2007 by 2% as compared to the same period in the prior year. The primary exchange rate movement that impacts net sales is the movement of the Euro compared to the U.S. dollar. The impact of exchange rate movements on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities.

U.S. net sales in the quarter ended June 30, 2007 of $374.8 million increased 8% over U.S. net sales of $345.8 million in the quarter ended June 30, 2006. International net sales in the quarter ended June 30, 2007 of $170.9 million increased 13% on a reported basis and 7% on a constant currency basis over international net sales of $150.7 million in the second quarter ended June 30, 2006. Bard’s six months ended June 30, 2007 U.S. net sales of $748.7 million increased 11% over the six months ended June 30, 2006 U.S. net sales of $674.4 million. Bard’s six months ended June 30, 2007 international sales of $325.2 million increased 13% on a reported basis and 7% on a constant currency basis over the six months ended June 30, 2006 international sales of $288.0 million.

26

Presented below is a discussion of consolidated net sales by disease state for the quarters and six months ended June 30, 2007 and 2006, respectively;

Product Group Summary of Net Sales

	For the Quarter Ended June 30,								For the Six Months Ended June 30,
(dollars in millions)	2007		2006		Change		Constant Currency		2007		2006		Change		Constant Currency
Vascular	$	135.9	$	119.7	14	%	10	%	$	263.6	$	233.4	13	%	10	%
Urology		160.9		147.5	9	%	8	%		316.1		280.2	13	%	11	%
Oncology		141.9		117.0	21	%	20	%		269.7		228.0	18	%	17	%
Surgical Specialties		86.5		94.5	(8	)%	(10	)%		183.6		182.6	1	%	(1	)%
Other		20.5		17.8	15	%	13	%		40.9		38.2	7	%	6	%
Total net sales	$	545.7	$	496.5	10	%	8	%	$	1,073.9	$	962.4	12	%	10	%

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products, electrophysiology products and surgical graft products. Consolidated net sales for the quarter ended June 30, 2007 of vascular products increased 14% on a reported basis (10% on a constant currency basis) compared to the prior year’s second quarter. U.S. net sales for the quarter ended June 30, 2007 of vascular products grew 11% compared to the prior year’s second quarter. International net sales for the quarter ended June 30, 2007 increased 17% on a reported basis (9% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of vascular products increased 13% on a reported basis (10% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2007 of vascular products grew 15% compared to the same period in the prior year. International net sales for the six months ended June 30, 2007 increased 11% on a reported basis (4% on a constant currency basis) compared to the same period in the prior year. The vascular group is the company’s most global business, with international net sales comprising 45% and 44% of consolidated net sales of vascular products for the quarter and six months ended June 30, 2007, respectively.

Consolidated net sales for the quarter ended June 30, 2007 of endovascular products increased 15% on a reported basis (12% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of endovascular products increased 16% on a reported basis (13% on a constant currency basis) compared to the same period in the prior year. The company’s percutaneous transluminal angioplasty balloon catheter, vena cava filter, stent graft and biopsy product lines contributed to the growth in this category.

Consolidated net sales for the quarter ended June 30, 2007 of electrophysiology products increased 25% on a reported basis (20% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of electrophysiology products increased 18% on a reported basis (13% on a constant currency basis) compared to the same period in the prior year. Strong sales performance in the company’s electrophysiology laboratory systems, steerable diagnostic catheter line and products for the diagnosis of atrial fibrillation have driven the growth in electrophysiology products for the quarter and six months ended June 30, 2007.

Consolidated net sales for the quarter ended June 30, 2007 of surgical graft products decreased 1% on a reported basis (3% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of surgical graft products increased 1% on a reported basis (decreased 2% on a constant currency basis) compared to the same period in the prior year.

Urology Products - Bard markets a wide range of products for the urology market, including basic drainage products, continence products, pelvic floor reconstruction products and urological specialty products. Bard also

27

markets the StatLock^® line of catheter stabilization devices, which are used to secure many of the catheters across Bard’s product portfolio. Consolidated net sales for the quarter ended June 30, 2007 of urology products were $160.9 million, an increase of 9% on a reported basis (8% on a constant currency basis) compared to the prior year’s second quarter. U.S. net sales of urology products represented 72% of consolidated net sales of urology products for the quarter ended June 30, 2007 and grew 9% compared to the prior year’s quarter. International net sales for the quarter ended June 30, 2007 of urology products increased 10% on a reported basis (5% on a constant currency basis) compared to the prior year’s quarter. Consolidated net sales for the six months ended June 30, 2007 of urology products were $316.1 million, an increase of 13% on a reported basis (11% on a constant currency basis) compared to the same period in the prior year. U.S. net sales of urology products represented 72% of consolidated net sales of urology products for the six months ended June 30, 2007 and grew 12% compared to the same period in the prior year. International net sales for the six months ended June 30, 2007 of urology products increased 15% on a reported basis (9% on a constant currency basis) compared to the same period in the prior year.

Basic drainage products represent the core of the company’s urology business. Consolidated net sales for the quarter ended June 30, 2007 of basic drainage products increased 5% on a reported basis (4% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the quarter ended June 30, 2007 of infection control Foley catheter products grew 11% on both a reported basis and constant currency basis compared to the same period in the prior year. Consolidated net sales for the six months ended June 30, 2007 of basic drainage products increased 6% on a reported basis (5% on a constant currency basis) compared to the same period in the prior year. Consolidated net sales for the six months ended June 30, 2007 of infection control Foley catheters grew 12% on both a reported basis and constant currency basis compared to the same period in the prior year.

Consolidated net sales for the quarter ended June 30, 2007 of urological specialty products, which include brachytherapy products and services, increased 7% on a reported basis (5% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of urological specialty products increased 7% on a reported basis (5% on a constant currency basis) compared to the same period in the prior year. Net sales of the company’s endourology products have gained momentum in recent quarters due to increased focus by the company’s urological specialty sales force.

Consolidated net sales for the quarter ended June 30, 2007 of continence products increased 5% on a reported basis (2% on a constant currency basis) compared to the prior year’s second quarter. The company’s pelvic floor reconstruction product line was the primary growth driver in the continence category for the quarter ended June 30, 2007. Consolidated net sales for the six months ended June 30, 2007 of continence products increased 8% on a reported basis (5% on a constant currency basis) compared to the same period in the prior year. Late in the second quarter ended June 30, 2007 the company launched a new line of surgical slings and additional configurations of its pelvic floor reconstruction product line.

Consolidated net sales for the quarter ended June 30, 2007 of the Statlock^® line of products, which was acquired as of April 10, 2006, increased 64% on both a reported basis and constant currency basis compared to the prior year’s second quarter.

Oncology Products - The company’s oncology products include specialty access products used primarily for chemotherapy. Consolidated net sales for the quarter ended June 30, 2007 of oncology products grew 21% on a reported basis (20% on a constant currency basis) compared to the prior year’s second quarter. U.S. net sales for the quarter ended June 30, 2007 of oncology products grew 24% compared to the prior year’s second quarter. International net sales for the quarter ended June 30, 2007 of oncology products grew 15% on a reported basis (9% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of oncology products grew 18% on a reported basis (17% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2007 of oncology products grew 20% compared to the same period in the prior year. International net sales for the six

28

months ended June 30, 2007 of oncology products grew 14% on a reported basis (8% on a constant currency basis) compared to the same period in the prior year. The company’s specialty access ports and peripherally-inserted central catheters (“PICCs”) were the primary contributors to the strong net sales growth in the oncology category for the six months ended June 30, 2007.

Surgical Specialty Products - Surgical specialty products include soft tissue repair, performance irrigation and hemostasis product lines. Consolidated net sales for the quarter ended June 30, 2007 of surgical specialty products decreased 8% on a reported basis (10% on a constant currency basis) compared to the prior year’s second quarter. U.S. net sales for the quarter ended June 30, 2007 of surgical specialty products decreased 15% compared to the prior year’s second quarter. International net sales for the quarter ended June 30, 2007 of surgical specialty products increased 11% on a reported basis (6% on a constant currency basis) compared to the prior year’s second quarter. During the second quarter ended June 30, 2007, the company made the decision to initiate both a voluntary recall and a withdrawal of its reusable Salute^® hernia fixation device from the market. The results for second quarter and six months ended June 30, 2007 included an accrual associated with this decision that reduced net sales by $2.3 million. Consolidated net sales for the six months ended June 30, 2007 of surgical specialty products increased 1% on a reported basis (decreased 1% on a constant currency basis) compared to the same period in the prior year. U.S. net sales for the six months ended June 30, 2007 of surgical specialty products decreased 3% compared to the same period in the prior year. International net sales for the six months ended June 30, 2007 of surgical specialty products grew 12% on a reported basis (7% on a constant currency basis) compared to the same period in the prior year. The decline in net sales for the quarter ended June 30, 2007 of surgical specialty products was due primarily to the net effect of (i) additional sales in the quarter ended June 30, 2006 resulting from the return to market of certain of the previously-recalled Composix^® Kugel^® hernia patch products (see below); (ii) the reduction in net sales associated with the decision to initiate both a voluntary recall and a withdrawal of the company’s reusable Salute^® hernia fixation device from the market as noted above; and (iii) backorders in the company’s hernia fixation and performance irrigation lines due to temporary product component issues. The decline in net sales growth for the six months ended June 30, 2007 was due primarily to those same factors. These component issues could continue and may impact consolidated net sales of surgical specialty products in subsequent quarters.

Consolidated net sales for the quarter ended June 30, 2007 of soft tissue repair products decreased 7% on a reported basis (8% on a constant currency basis) compared to the prior year’s second quarter. Consolidated net sales for the six months ended June 30, 2007 of soft tissue repair products increased 2% on a reported basis (1% on a constant currency basis) compared to the same period in the prior year. The decline in net sales for the quarter ended June 30, 2007 of soft tissue repair products was due primarily to the factors noted above. The decline in net sales growth for the six months ended June 30, 2007 was due primarily to those same factors.

On December 29, 2005, the company initiated a voluntary Class I product recall of its Bard^® Composix^® Kugel^® Mesh X-Large Patch intended for ventral hernia repair. The company’s sales results for the quarter and year ended December 31, 2005 included a net sales reduction of $7.8 million in the surgical specialty group due to this recall, resulting in a 1 percentage point reduction in 2005 consolidated ongoing net sales growth on a constant currency basis. Following the recall, the U.S. Food and Drug Administration (“FDA”) conducted a follow-up inspection and issued an FDA Form-483 to the company’s Davol, Inc. subsidiary identifying certain observations. The company has addressed these observations.

On March 15, 2006, the company voluntarily expanded the December 29, 2005 recall to include certain manufacturing lots of the large Composix^® Kugel^® patch and large Composix^® circle. In December 2006, the company decided to voluntarily expand the March recall to include additional manufacturing lots and initiated the expanded recall on January 10, 2007. The impact of these subsequent recalls was not material to the company’s full year 2006 financial results.

Following the expanded recall, the FDA conducted a follow-up inspection and issued an FDA Form-483 to Davol identifying certain observations regarding Davol’s quality systems. The company has responded and is in

29

the process of addressing these observations. On April 25, 2007, Davol received a Warning Letter from the New England District Office of the FDA resulting from the follow-up inspection. The Warning Letter relates specifically to non-conformances in Davol’s quality systems previously identified in the related Form-483. The Warning Letter states that, until Davol resolves the outstanding issues covered by the Warning Letter, no premarket submissions for Class III devices to which the non-conformances are reasonably related will be cleared or approved. Davol presently has no such submissions before the FDA. The company has responded to all observations in the Warning Letter and intends to fully implement corrective actions to address the FDA’s concerns. The company has met with FDA representatives to advise them of the progress being made in addressing observations in the Warning Letter and has proposed a re-inspection of the Davol facility in the first quarter of 2008. The company cannot, however, give any assurances that the FDA will be satisfied with its response to the Warning Letter or as to the expected date of resolution of matters included in the Warning Letter.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ (OEM) products. Consolidated net sales of other products for the quarter ended June 30, 2007 were $20.5 million, an increase of 15% on a reported basis (13% increase on a constant currency basis) compared to the prior year’s second quarter.
Consolidated net sales of other products for the six months ended June 30, 2007 were $40.9 million, an increase of 7% on a reported basis (6% on a constant currency basis) compared to the same period in the prior year.

Costs and Expenses

The company’s costs and expenses consist of costs of goods sold, marketing, selling and administrative expense, research and development expense, interest expense and other (income) expense, net. Costs of goods sold consist principally of the manufacturing and distribution costs of the company’s products as well as royalties and the amortization of intangible assets. Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. Research and development expense consists principally of expenses incurred with respect to internal research and development activities, milestone payments for third-party research and development activities and purchased R&D costs arising from the company’s business development activities. Purchased R&D payments may impact the comparability of the company’s results of operations between periods. Interest expense consists of interest charges on indebtedness. Other (income) expense, net consists principally of interest income, foreign exchange gains and losses and other items, some of which may impact the comparability of the company’s results of operations between periods.

The following is a summary of major costs and expenses as a percentage of net sales for the quarters and six months ended June 30, 2007 and 2006, respectively:

	Quarter Ended June 30,				Six Months Ended June 30,
	2007		2006		2007		2006
Cost of goods sold	39.7	%	39.2	%	39.4	%	38.7	%
Marketing, selling and administrative expense	29.4	%	30.9	%	29.3	%	30.7	%
Research and development expense	6.4	%	7.5	%	6.1	%	7.9	%
Interest expense	0.5	%	0.9	%	0.5	%	1.0	%
Other (income) expense, net	(1.6	)%	(1.5	)%	(1.5	)%	(1.6	)%
Total costs and expenses	74.4	%	77.0	%	73.8	%	76.7	%

Cost of goods sold - The acquisition of Venetec International, Inc. (“Venetec”) in the second quarter of 2006 increased cost of goods sold as a percentage of net sales by approximately 70 basis points sequentially due to the amortization of intangible assets for the quarter ended June 30, 2006. The company’s cost of goods sold as a percentage of net sales for the quarter ended June 30, 2007 was 39.7%, an increase of 50 basis points from the cost of goods sold as a percentage of net sales of 39.2% for the quarter ended June 30, 2006. Included in these

30

costs were charges totaling $3.4 million, or 0.6% of net sales, associated with the decision in the second quarter ended June 30, 2007 to initiate both a voluntary recall and a withdrawal of the company’s reusable Salute^® hernia fixation device from the market (see above). The company’s cost of goods sold as a percentage of net sales for the six months ended June 30, 2007 was 39.4%, an increase of 70 basis points from the cost of goods sold as a percentage of net sales for the six months ended June 30, 2006 of 38.7%.

Marketing, selling and administrative expense - The company’s marketing, selling and administrative costs as a percentage of net sales for the quarter ended June 30, 2007 was 29.4%. Marketing, selling and administrative costs as a percentage of net sales for the quarter ended June 30, 2006 was 30.9%. The company’s marketing, selling and administrative costs as a percentage of net sales for the six months ended June 30, 2007 was 29.3%. Marketing, selling and administrative costs as a percentage of net sales for the six months ended June 30, 2006 was 30.7%. The decrease in expense as a percentage of net sales was a result of tight spending controls in certain marketing, selling and administrative areas.

Research and development expense - Research and development expenses are comprised of expenses related to internal research and development activities, milestone payments for third-party research and development activities and purchased R&D costs arising from the company’s business development activities. The components of internal research and development expenses include: salary and benefits, allocated overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract services and milestone payments for third-party research and development. All research and development costs are expensed as incurred. Included in the research and development costs in the second quarter ended June 30, 2007 was purchased R&D of approximately $1.6 million pretax, compared to the $6.4 million pretax of purchased R&D for same period in the prior year. Included in the research and development costs for the six months ended June 30, 2007 was purchased R&D of approximately $1.6 million pretax, compared to the $16.8 million pretax of purchased R&D for the six months ended June 30, 2006.

Interest expense - Interest expense for the quarter ended June 30, 2007 decreased to $3.0 million from the $4.5 million for the quarter ended June 30, 2006. Interest expense for the six months ended June 30, 2007 decreased to $5.9 million from the $9.2 million for the six months ended June 30, 2006. The reduction in interest expense for the three and six months ended June 30, 2007 periods was due to a decline in outstanding borrowings.

Other (income) expense, net - The table below presents the components of other (income) expense, net for the quarters and six months ended June 30, 2007 and 2006, respectively:

	For the Quarter Ended June 30,						For the Six Months Ended June 30,
(dollars in millions)	2007			2006			2007			2006
Interest income	$	(8.2	)	$	(6.3	)	$	(15.3	)	$	(14.1	)
Foreign exchange (gains) losses		(0.5	)		0.3			(0.7	)		—
Investment gains		—			(1.6	)		—			(1.6	)
Other, net		(0.1	)		—			(0.2	)		0.4
Total other (income) expense, net	$	(8.8	)	$	(7.6	)	$	(16.2	)	$	(15.3	)

Interest income - For the quarter ended June 30, 2007, interest income was approximately $8.2 million, compared to approximately $6.3 million for the quarter ended June 30, 2006. For the six months ended June 30, 2007, interest income was approximately $15.3 million, compared to approximately $14.1 million for the six months ended June 30, 2006. The increase in 2007 was primarily due to higher cash and cash equivalents balances.

31

Income tax provision - The following is a reconciliation between the effective tax rates and the statutory rates for the quarters and six months ended June 30, 2007 and 2006, respectively:

	For the Quarter Ended June 30,		For the Six Months Ended June 30,
	2007	2006	2007	2006
U.S. federal statutory rate	35%	35%	35%	35%
State income taxes, net of federal benefit	2%	1%	2%	1%
Operations taxed at less than U.S. rate	(7)%	(9)%	(8)%	(10)%
Other, net	—	2%	—	2%
Effective tax rate	30%	29%	29%	28%

The company’s effective tax rate for the quarter ended June 30, 2007 increased to 30%, compared to 29% for the same period in 2006. The company’s effective tax rate for the six months of operations ended June 30, 2007 increased to 29% compared to 28% for the same period in 2006. This change is principally due to the impact associated with the purchased R&D and the decision to initiate both a voluntary recall and a withdrawal of the company’s reusable Salute^® hernia fixation device from the market, as noted above.

Net Income and Earnings Per Share

Bard reported consolidated net income for the quarter ended June 30, 2007 of $97.5 million. Consolidated net income for the quarter ended June 30, 2006 was $81.4 million. Bard reported diluted earnings per share for the quarter ended June 30, 2007 of $0.91, an increase of 20% from diluted earnings per share for the quarter ended June 30, 2006 of $0.76. Bard reported consolidated net income for the six months ended June 30, 2007 of $199.1 million. Consolidated net income for the six months ended June 30, 2006 was $162.5 million. Bard reported diluted earnings per share for the six months ended June 30, 2007 of $1.86, an increase of 22% from diluted earnings per share for the six months ended June 30, 2006 of $1.52.

As described above under “Costs and Expenses,” certain items in the quarters and six months ended June 30, 2006 and June 30, 2007 impact the comparability of the company’s results of operations between periods.

Liquidity and Capital Resources from Continuing Operations

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are: cash flows generated from operating activities, capital expenditures, investments in businesses and technologies, cash dividends and common stock repurchases. Cash provided from operations continues to be the company’s primary source of funds. Should it be necessary, the company believes it could borrow adequate funds at competitive terms. The table below summarizes liquidity measures for Bard as of June 30, 2007 and 2006, respectively:

	2007		2006
(dollars in millions)
Cash and cash equivalents	$	497.5	$	420.0
Short-term investments		122.3		101.4
Subtotal	$	619.8	$	521.4
Working capital	$	1,036.7	$	579.3
Current ratio		5.30/1		2.11/1
Total debt	$	150.6	$	231.4

Short-term investments that have original maturities of ninety days or less are considered cash equivalents. Working capital is defined as current assets less current liabilities. Current ratio is defined as the ratio of current assets to current liabilities.

32

The following table and explanations provide cash flow data from continuing operations for the six months ended June 30, 2007 and 2006, respectively:

	2007			2006
(dollars in millions)
Net cash provided by operating activities	$	237.7		$	131.4
Net cash used in investing activities	$	(105.2	)	$	(315.8	)
Net cash used in financing activities	$	(56.5	)	$	(160.4	)

Operating activities - For the six months ended June 30, 2007, the company generated $237.7 million cash flow from operations, $106.3 million more than the cash flow from operations reported for the six months ended June 30, 2006. Adjustments to reconcile net income to net cash provided by operating activities were $38.6 million and $(31.1) million for the six months ended June 30, 2007 and 2006, respectively. The increase in cash flow from operations was due primarily to a tax payment made in the first quarter of 2006 related to the company’s repatriation of foreign earnings in 2005 pursuant to the AJCA and other improvements in working capital balances. For the six months ended June 30, 2007, net income of $199.1 million increased $36.6 million over net income reported for the six months ended June 30, 2006. Depreciation expense was approximately $24.3 million for the six months ended June 30, 2007 and $22.2 million for the six months ended June 30, 2006. Amortization expense was approximately $14.5 million for the six months ended June 30, 2007 and $11.7 million for the six months ended June 30, 2006.

Investing activities - For the six months ended June 30, 2007, the company used $105.2 million in cash for investing activities, $210.6 million less than the $315.8 million used for investing activities reported for the six months ended June 30, 2006. In April 2006, the company paid approximately $166.0 million for the outstanding stock of Venetec International, Inc. Capital expenditures amounted to $25.2 million and $37.6 million for the six months ended June 30, 2007 and 2006, respectively. These cash expenditures were financed primarily with cash from operations.

Financing activities - For the six months ended June 30, 2007, the company used $56.5 million in cash for financing activities, $103.9 million less than the $160.4 million used in financing activities reported for the six months ended June 30, 2006. Cash flow related to financing activities included changes in borrowings, equity proceeds related to option exercises, purchases of company stock and dividend payments. Total debt was $150.6 million at June 30, 2007 and $231.4 million at June 30, 2006. Total debt to total capitalization was 7.4% and 12.2% at June 30, 2007 and 2006, respectively. For the six months ended June 30, 2007, the company spent approximately $81.3 million to purchase 980,000 shares of common stock of the company. For the six months ended June 30, 2006, the company spent approximately $102.6 million to purchase 1,497,600 shares of common stock of the company. At June 30, 2007, a total of approximately $217.4 million remains under the company’s $500 million share purchase authorization approved by the Board of Directors in 2005. The company paid cash dividends of $0.28 per share in the six months ended June 30, 2007 and $0.26 per share in the six months ended June 30, 2006.

On June 28, 2007, the company amended its existing domestic syndicated bank credit facility with a $400 million five-year credit agreement that expires in June 2012. The amended credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. There were no outstanding borrowings or commercial paper borrowings at June 30, 2007 and December 31, 2006. In addition, on October 21, 2005, a wholly owned foreign subsidiary of the company entered into a $250 million syndicated bank credit facility to be used for general corporate needs, including in support of the company’s decision in 2005 to repatriate undistributed foreign earnings under the AJCA. Loans under the facility bear interest at the company’s option at a fixed spread to LIBOR or the higher of prime rate and 0.50% over the federal funds rate. The facility expires in October 2008. There were no outstanding borrowings under the facility at June 30, 2007 and December 31, 2006.

33

At June 30, 2007, the company had $149.8 million of unsecured notes that mature in 2026 and pay a semi-annual coupon of 6.70%. The coupon interest closely approximates the effective annual cost of the notes. The market value of the notes approximated $153.4 million at June 30, 2007.

At June 30, 2007, the company’s long-term debt was rated “A” by Standard and Poor’s and “Baa1” by Moody’s, and the company’s commercial paper ratings were “A-1” by Standard and Poor’s and “P-2” by Moody’s. The company believes that this overall financial strength gives Bard sufficient financing flexibility.

Commitments and Contingencies

Based upon the expiration of statutes of limitations and/or the conclusion of tax examinations in several jurisdictions, the company believes it is reasonably possible that the total amount of previously unrecognized tax benefits may decrease by up to $20.0 million within 12 months of June 30, 2007. There have been no other significant changes to the company’s contractual obligations and commercial commitments in the first six months of 2007 as summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the company’s Annual Report on Form 10-K/A for the year ended December 31, 2006. See Note 3 Income Tax Expense in the notes to the unaudited condensed consolidated financial statements contained in this report.

Legal - On November 27, 2006, the company’s Urological Division received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes. The subpoena seeks documents related to the Division’s brachytherapy business. The company is cooperating with the government’s request and is in the process of responding to the subpoena. The inquiry is in a preliminary stage and, therefore, the likelihood of an adverse outcome cannot be assessed at this time. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period.

Approximately 100 federal and state lawsuits involving individual claims, as well as three putative class actions, have been filed or asserted against the company with respect to its Bard^® Composix^® Kugel^® product intended for ventral hernia repair (collectively, the “Composix Claims”). The company voluntarily recalled certain sizes and lots of the product beginning in December 2005. The actions generally seek damages for personal injury resulting from use of the product and the putative class actions, none of which has been certified, also seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. On June 22, 2007, the Judicial Panel on Multidistrict Litigation transferred Composix lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings. The federal actions have been transferred to the United States District Court for the District of Rhode Island.

The Composix Claims are at an early stage and, therefore, the company cannot reasonably predict the outcome of the proceedings or determine an estimate, or a range of estimates, of potential damages, nor the time frame in which they may be resolved. While the company intends to vigorously defend the Composix Claims, it cannot give any assurances that the Composix Claims will not have a material adverse impact on the company’s result of operations in a future period or the company’s financial position or liquidity.

On February 21, 2007, Southeast Missouri Hospital filed a putative class action complaint on behalf of itself and all others similarly situated against the company and another manufacturer under the caption Southeast Missouri Hospital v. C. R. Bard, Inc., et al. (Civil Action No. 1:07-cv-00031, United States District Court, Eastern District of Missouri, Southeastern District). The plaintiff alleges that the company and the other defendant conspired to exclude competitors from the market and to maintain the company’s market share by engaging in conduct in violation of state and federal antitrust laws. The plaintiff seeks injunctive relief and money damages. Antitrust damages are subject to trebling. The company intends to defend this matter vigorously. At this time, it is not possible to assess the likelihood of an adverse outcome or determine an

34

estimate, or a range of estimates, of potential damages. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period or the company’s financial position or liquidity.

Management’s Use of Non-GAAP Measures

“Net sales on a constant currency basis” is a non-GAAP financial measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP financial measures are intended to supplement the applicable GAAP disclosures and should not be viewed as a replacement of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The SEC defines “critical accounting policies” as those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. The following is not intended to be a comprehensive list of all of the company’s critical accounting policies. The company’s significant accounting policies are more fully described in the company’s notes to condensed consolidated financial statements. In many cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States, with no need for management’s judgment in their application. The critical accounting policies described below are areas in which management’s judgment in selecting an available alternative might produce a materially different result.

Revenue Recognition - The company recognizes product revenue, net of discounts and rebates, when persuasive evidence of a sales arrangement exists, title and risk of loss has transferred, the buyer’s price is fixed or determinable, contractual obligations have been satisfied and collectibility is reasonably assured. Unless agreed otherwise, the company’s terms with domestic distributors provide that title and risk of loss pass F.O.B. origin. Certain sales to domestic and European distributors are F.O.B. destination. For arrangements where the company’s terms state F.O.B. destination, the company records sales on this basis. In the case of consignment inventories, revenues and associated costs are recognized upon the notification of usage by the customer.

Inventories - Inventories are stated at the lower of cost or market. For most domestic divisions, cost is determined using the last-in-first-out (“LIFO”) method. For all other inventories, cost is determined using the first-in-first-out (“FIFO”) method. Due to changing technologies and cost containment, the difference between the inventory valuation under the LIFO method and the FIFO method is not significant.

Share-Based Compensation - The company accounts for share-based compensation in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 123 (revised 2004), Share-Based Payment (“FAS 123R”), as interpreted by SEC Staff Accounting Bulletin No. 107. Under the fair value provisions of this statement, share-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the date of grant, the company utilizes a binomial model. Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free interest rate and dividend yield. The risk-free interest rate and dividend yield are based on factual data derived from public sources. The expected stock-price volatility and option life assumptions require significant judgment which makes them critical accounting estimates.

35

The company’s expected volatility is based upon weightings of the historical volatility of the company’s stock and the implied volatility from publicly traded options. The company reviews the trading volumes and option life of its publicly traded options in order to determine the appropriate weighting of implied volatility. This approach is used as a predictor of future realized and implied volatilities and is directly related to stock option valuations.

With respect to the weighted-average option life assumption, the company considers the exercise behavior of past grants and models the pattern of aggregate exercises.

As share-based compensation expense recognized in the consolidated statement of income is based on awards ultimately expected to vest, the amount of expense has been reduced for estimated forfeitures. FAS 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on historical experience.

Legal Reserve Estimates - The company is at times involved in legal actions, the outcomes of which are not within the company’s complete control and may not be known for extended periods of time. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures. A liability is recorded in the company’s consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements.

Income Taxes - The company operates in multiple taxing jurisdictions, both within the United States and outside the United States. The company has filed tax returns with positions that may be challenged by the tax authorities. These positions relate to, among others, transfer pricing, the deductibility of certain expenses, intercompany transactions as well as other matters. Although the outcome of tax audits is uncertain, in management’s opinion, adequate provisions for income taxes have been made for potential liabilities resulting from such matters. The company regularly assesses its tax position for such matters and includes reserves for those differences in position. The reserves are utilized or reversed once the statute of limitations has expired and/or upon the conclusion of the tax examination. The company believes that the ultimate outcome of these matters will not have a material impact on its financial position or liquidity but may be material to the income tax provision and net income in a future period. Effective January 1, 2007, the company adopted FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109 (“FIN 48”).

Allowance for Doubtful Accounts, Customer Rebates and Inventory Writedowns - Management makes estimates of the uncollectibility of the company’s accounts receivable, amounts that are rebated to specific customers in accordance with contractual requirements and inventory adjustments to reflect inventory valuation at the lower of cost or market. In estimating the reserves necessary for the allowance for doubtful accounts, management considers historical bad debt trends, customer concentrations, customer creditworthiness and current economic trends. The company establishes an allowance for doubtful accounts for estimated amounts that are uncollectible from customers. In estimating the allowance for customer rebates, management considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer specific trend analysis and contractual commitments including the stated rebate rate. The company establishes an allowance for customer rebates and reduces sales for such rebate amounts. In estimating the adjustment for inventory writedowns, management considers product obsolescence, quantity on hand, future demand for the product and other market-related conditions. The company records an adjustment for inventory writedowns when such conditions cause the inventory market value to be below carrying value. The company records such adjustments to cost of sales in the period in which the condition exists.

It is possible that the underlying factors discussed above for the allowance for doubtful accounts, customer rebates and inventory writedowns could change. Depending on the extent and nature of the change to the underlying factors, the impact to the company’s financial position and results of operations could be material in the period of change.

Valuation of Purchased R&D, Goodwill and Intangible Assets - When the company acquires another company, the purchase price is allocated, as applicable, between purchased R&D, other identifiable intangible

36

assets, tangible assets and goodwill as required by generally accepted accounting principles in the United States. Purchased R&D is defined as the value assigned to those projects for which the related products have not received regulatory approval and have no alternative future use. Determining the portion of the purchase price allocated to purchased R&D and other intangible assets requires the company to make significant estimates. The amount of the purchase price allocated to purchased R&D and other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods. For purchased R&D, these methodologies include consideration of the risk of the project not achieving commercial feasibility.

Goodwill represents the excess of the aggregate purchase price over the fair value of net assets, including purchased R&D, of the acquired businesses. Goodwill is tested for impairment annually, or more frequently if changes in circumstances or the occurrence of events suggest an impairment exists. The test for impairment requires the company to make several estimates about fair value, most of which are based on projected future cash flows. The company’s estimates associated with the goodwill impairment tests are considered critical due to the amount of goodwill recorded on the company’s consolidated balance sheets and the judgment required in determining fair value amounts, including projected future cash flows.

Intangible assets consist primarily of patents, distribution agreements and other intellectual property, which are amortized using the straight-line method over their estimated useful lives, ranging from 8 to 24 years. The company reviews these intangible assets for impairment annually or as changes in circumstances or the occurrence of events suggest the remaining value is not recoverable.

Pension Plans - The company sponsors pension plans covering substantially all domestic employees and certain foreign employees who meet eligibility requirements. Several statistical and other factors that attempt to anticipate future events are used in calculating the expense and liability related to the plans. These factors include assumptions about the discount rate, expected return on plan assets and rate of future compensation increases as determined by the company, within certain guidelines. In addition, the company’s actuarial consultants also use subjective factors, such as withdrawal and mortality rates, to estimate these factors. The actuarial assumptions used by the company may differ materially from actual results due to changing market and economic conditions, higher or lower withdrawal rates or longer or shorter life spans of the participants. These differences may have a significant effect on the amount of pension expense recorded by the company.

New Accounting Pronouncements - In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“FAS 157”), which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The provisions of FAS 157 are effective as of the beginning of Bard’s 2008 fiscal year. The company does not expect the adoption of FAS 157 to have a material impact on its financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities—including an amendment of FASB Statement No. 115 (“FAS 159”). FAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. FAS 159 is expected to expand the use of fair value measurement, which is consistent with the long-term measurement objectives for accounting for financial instruments. FAS 159 is effective as of the beginning of Bard’s 2008 fiscal year with early adoption permitted. The company does not expect the adoption of FAS 159 to have a material impact on its financial statements.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private

37

Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of life-sustaining medical devices. These devices are often utilized on, or permanently or temporarily implanted in, patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims, (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, recalls, field corrections or regulatory enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, financial position, liquidity and results of operations. For further discussion of risks applicable to our business, see “Risk Factors” in our Annual Report on Form 10-K/A.

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties, but the most significant factors, in addition to those addressed above, that could adversely affect our business or cause the actual results to differ materially from those expressed or implied include, but are not limited to:

Effective management of and reaction to risks involved in our business, including:

• the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing process and supply chain programs or in connection with the integration of acquired businesses;

• the effects of negative publicity concerning our products, which could result in product withdrawals or decreased product demand and which could reduce market or governmental acceptance of our products;

• the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and integrate such transactions or to obtain agreements for such transactions with favorable terms;

• the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

• the ability to maintain or increase research and development expenditures;

• the uncertainty of whether increased research and development expenditures and sales force expansion will result in increased sales;

• the ability to maintain our effective tax rate and uncertainty related to tax audits, appeals and litigation;

• the risk that the company may not successfully implement its new Enterprise Resource Planning (“ERP”) information system, which could adversely affect the company’s results of operations in future periods or its ability to meet the ongoing requirements of Section 404 of the Sarbanes-Oxley Act of 2002;

• internal factors, such as retention of key employees, including sales force employees;

• the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others;

38

• changes in factors and assumptions employed in the application of FAS 123R, or actual results that differ from our assumptions on stock valuation and employee option exercise patterns, which could cause compensation expense recorded in future periods to differ significantly from the compensation expense recorded in the current period and, as a result, materially impact the company’s results of operations;

• damage to any company facility, which could render the company unable to manufacture one or more products (as the company may utilize only one manufacturing facility for certain of its major products) and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets; and

• the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets.

Competitive factors, including:

• the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures and more significant and complex contracts than in the past, both in the United States and abroad;

• development of new products or technologies by competitors having superior performance compared to our current products or products under development;

• technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

• attempts by competitors to gain market share through aggressive marketing programs; and

• reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

• the ability to complete planned clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

• lengthy and costly regulatory approval processes, which may result in lost market opportunities;

• delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

• the suspension or revocation of authority to manufacture, market or distribute existing products;

• the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

• performance, efficacy or safety concerns for existing products, whether scientifically justified or not, that may lead to product withdrawals, recalls, field corrections, regulatory enforcement actions, litigation or declining sales, including adverse events relating to the company’s vena cava filters and hernia repair products;

• FDA inspections resulting in FDA Form-483 observations and/or Warning Letters identifying deficiencies in the company’s current good manufacturing practices and/or quality systems; warning letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA for products to which the deficiencies are reasonably related and/or civil penalties;

• the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

39

• difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials or other interruptions of the supply chain; and

• customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organization.

Governmental action, including:

• the impact of continued healthcare cost containment;

• new laws and judicial decisions related to health care availability, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce reimbursements for procedures that use the company’s products;

• changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

• the impact of more vigorous compliance and enforcement activities affecting the healthcare industry in general or the company in particular;

• changes in the tax or environmental laws or standards affecting our business which could require facility upgrades or process changes and could affect production rates and output; and

• compliance costs and potential penalties and remediation obligations in connection with environmental laws, including, without limitation, regulations regarding air emissions, waste water discharges and solid waste.

Legal disputes, including:

• disputes over intellectual property rights;

• product liability claims, including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings;

• claims asserting securities law violations;

• claims asserting, and subpoenas seeking information regarding, violations of law in connection with federal and/or state healthcare programs such as Medicare or Medicaid;

• derivative shareholder actions;

• claims and subpoenas asserting antitrust violations;

• environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

• commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements and acquisition or sale agreements.

General economic conditions, including:

• international and domestic business conditions;

• political instability in foreign countries;

• interest rates;

40

• foreign currency exchange rates; and

• changes in the rate of inflation.

Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Bard operates on a global basis and therefore is subject to the exposures that arise from foreign exchange rate fluctuations. The company manages these exposures using operational and economic hedges as well as derivative financial instruments. The company’s foreign currency exposures may change over time as changes occur in the company’s international operations. The company’s objective in managing its exposures to foreign currency fluctuations is to minimize earnings and cash flow volatility associated with assets, liabilities, net investments and probable commitments denominated in foreign currencies. In order to reduce the risk of foreign currency exchange rate fluctuations, the company will from time to time enter into derivative financial instruments to hedge a portion of its expected foreign currency denominated cash flow from operations. The instruments that the company uses for hedging are forward contracts and options with major financial institutions. The company expects that the changes in fair market value of such contracts will have a high correlation to the price changes in the related hedged cash flow. The principal currencies the company hedges are the Euro, the British Pound, the Mexican Peso and the Japanese Yen. Any gains and losses on these hedge contracts are expected to offset changes in the value of the related exposure. Bard’s risk management guidelines prohibit entering into financial instruments for speculative purposes. The company enters into foreign currency transactions only to the extent that foreign currency exposure exists. A sensitivity analysis of changes in the fair value of all foreign exchange derivative contracts at June 30, 2007 indicates that if the U.S. dollar uniformly strengthened by 10% against all currencies, the fair value of these contracts would increase by $0.3 million, and if the U.S. dollar uniformly weakened by 10% against all currencies, the fair value of these contracts would increase by $1.7 million. Any gains and losses on the fair value of derivative contracts would be largely offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis.

In December 1996, the company issued $150.0 million of 6.70% notes due 2026. In the fourth quarter of 2006, approximately $0.2 million of the notes were redeemed and the remaining balance of approximately $149.8 million is included in long-term debt. The market value of the notes approximated $153.4 million at June 30, 2007. Assuming a 100 basis point increase or decrease in U.S. interest rates and assuming that the notes are held to maturity, the market value of the notes would approximate $137.9 million or $171.5 million, respectively, on June 30, 2007.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of June 30, 2007. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2007, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) provide reasonable assurance that the disclosure controls and procedures are effective to accomplish their objectives.

41

The company is in the process of implementing a new ERP information system to manage its business operations. Although the transition has proceeded to date without material adverse effects, the possibility exists that our migration to the new ERP information system could adversely affect the company’s controls and procedures. The process of implementing new information systems could adversely impact our ability to do the following in a timely manner: accept and process customer orders, receive inventory and ship products, invoice and collect receivables, place purchase orders and pay invoices and perform all other business transactions related to the accounting, order entry, purchasing and supply chain processes within the ERP system.

42

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company were to be determined to be invalid or unenforceable, the company might be required to reduce the value of the patent on the company’s balance sheet and to record a corresponding charge, which could be significant in amount.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for any remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined.

The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial position or liquidity. However, one or more of the proceedings could be material to the company’s business and results of operations for a future period.

On November 27, 2006, the company’s Urological Division received a subpoena issued by the Department of Health and Human Services, Office of Inspector General, under the authority of the federal healthcare fraud and false claims statutes. The subpoena seeks documents related to the Division’s brachytherapy business. The company is cooperating with the government’s request and is in the process of responding to the subpoena. The inquiry is in a preliminary stage and, therefore, the likelihood of an adverse outcome cannot be assessed at this time. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period.

Approximately 100 federal and state lawsuits involving individual claims, as well as three putative class actions, have been filed or asserted against the company with respect to its Bard^® Composix^® Kugel^® product intended for ventral hernia repair (collectively, the “Composix Claims”). The company voluntarily recalled certain sizes and lots of the product beginning in December 2005. The actions generally seek damages for personal injury resulting from use of the product and the putative class actions, none of which has been certified, also seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. On June 22, 2007, the Judicial Panel on Multidistrict Litigation transferred Composix lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings. The federal actions have been transferred to the United States District Court for the District of Rhode Island.

43

The Composix Claims are at an early stage and, therefore, the company cannot reasonably predict the outcome of the proceedings or determine an estimate, or a range of estimates, of potential damages, nor the time frame in which they may be resolved. While the company intends to vigorously defend the Composix Claims, it cannot give any assurances that the Composix Claims will not have a material adverse impact on the company’s result of operations in a future period or the company’s financial position or liquidity.

On February 21, 2007, Southeast Missouri Hospital filed a putative class action complaint on behalf of itself and all others similarly situated against the company and another manufacturer under the caption Southeast Missouri Hospital v. C. R. Bard, Inc., et al. (Civil Action No. 1:07-cv-00031, United States District Court, Eastern District of Missouri, Southeastern District). The plaintiff alleges that the company and the other defendant conspired to exclude competitors from the market and to maintain the company’s market share by engaging in conduct in violation of state and federal antitrust laws. The plaintiff seeks injunctive relief and money damages. Antitrust damages are subject to trebling. The company intends to defend this matter vigorously. At this time, it is not possible to assess the likelihood of an adverse outcome or determine an estimate, or a range of estimates, of potential damages. The company cannot give any assurances that this matter will not have a material adverse impact on the company’s results of operations in a future period or the company’s financial position or liquidity.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c)

	Issuer Purchases of Equity Securities
		Open Market Purchases
Period	Employee Benefit Plan Shares Surrendered For Taxes(1)	Total Number of Shares Purchased	Average Price Paid Per Share		Total Approximate Dollar Value Purchased as Part of Publicly Announced Program(2)		Maximum Approximate Dollar Value that May Yet Be Purchased Under Publicly Announced Program(2)
April 1 - April 30, 2007	5,050	50,000	$	83.29	$	4,100,000	$	294,600,000
May 1 - May 31, 2007	1,199	930,000		82.96		77,200,000		217,400,000
June 1 - June 30, 2007	380	—		—		—		217,400,000
Total	6,629	980,000	$	82.98	$	81,300,000	$	217,400,000

(1) Transactions represent the purchase of restricted shares from employees to satisfy tax withholding requirements on the vesting of equity-based awards. None of these transactions were made in the open market.

(2) On December 14, 2005, the Board of Directors approved the repurchase of up to $500 million of the common stock of the company.

Item 4. Submission of Matters to a Vote of Security Holders

The company’s annual meeting of shareholders was held on April 18, 2007. The information set forth in Part II, Item 4 of the company’s quarterly report on Form 10-Q for the period ended March 31, 2007 is hereby incorporated by reference.

Item 5. Other Information

Our policy governing transactions in our securities by our directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. We anticipate that from time to time, the company’s executive officers may establish trading plans relating to our common stock under Rule 10b5-1. Our current intention is to disclose details regarding individual trading plans on our website.

44

Item 6. Exhibits

(a) Exhibit 12.1 – Computation of Ratio of Earnings to Fixed Charges

(b) Exhibit 31.1 – Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer

(c) Exhibit 31.2 – Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer

(d) Exhibit 32.1 – Section 1350 Certification of Chief Executive Officer

(e) Exhibit 32.2 – Section 1350 Certification of Chief Financial Officer

45

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	C. R. BARD, INC.
	(Registrant)
	/s/    TODD C. SCHERMERHORN
	Todd C. Schermerhorn Senior Vice President and Chief Financial Officer
Date: July 27, 2007
	/s/    FRANK LUPISELLA JR.
	Frank Lupisella Jr. Vice President and Controller

46